GlaxoSmithKline will pay $600 million to state and federal authorities, while $150 million will be for a criminal fine.
The defective drugs were produced between 2001 and 2005.
“Today’s settlement reminds the pharmaceutical industry that they must observe those standards and reflects the commitment of Federal law enforcement organizations to pursue improper and illegal conduct that places health care consumers at risk,” Patrick E. McFarland, said in a statement. MacFarland is the inspector general of the U.S. Office of Personnel Management.
GlaxoSmithKline is a global pharmaceutical company specializing in vaccines, and biologics. Their headquarters are located in London. Only Johnson & Johnson and Pfizer generate more revenues than Glaxo. They are responsible for many popular medications such as Advair, Alli, Avodart, Avandia, Valtrex, Tums, Lanoxin, Horlicks and many more.
